With demand comes innovation. Americas Antibody Congress is the only antibody event which emphasizes new data and non-repetitive talks as a requirement to speak. In 2017, we will continue our tradition of focusing on the new. We know there is an epidemic of " conference fatigue " plaguing the industry - fght back with us!
Featuring content on Antibody Engineering, Clinical and Commercial Development, and Therapeutic Foucs Areas of Infectious Diseases and Oncology, Americas Antibody Congress will include over 40 hours of new preclinical and clinical data presented by our biopharma and academic partners
Antibody-based drugs are having a profound impact on the pharmaceutical industry. Genentech's Tecentriq , Taiho Oncology, Inc.'s LONSURF , and Eli Lilly and Company's CYRAMZA were approved by the FDA in 2016. With more expected, antibody-based drugs are proving their worth in the clinic and to the patient.
Join us and hundreds of your industry colleagues as they learn, meet and do business in 2017.